Propanc Biopharma provides shareholder update

Propanc Biopharma (PPCB) announced a shareholder update including recent corporate developments and forecast for 2025/26. Propanc has raised approximately $30 million since inception, culminating in the Company’s lead asset ready to commence clinical development and a backup clinical compound entering preclinical stage. Supported by an established and growing IP portfolio, Propanc intends to pursue strategic collaborations to finance and advance these strategic assets along the development pathway to future R&D milestones where significant commercial value may be realized. The combined market size forecast for the selected target therapeutic indications for PRP, pancreatic and ovarian cancers, is $18.1 billion in 2029, according to Grandview Research and iHealthcareAnalyst, respectively.